Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The FDA has accepted a supplemental new drug application for selinexor plus ruxolitinib in myelofibrosis, setting a target action date of June 28, 2027. If approved, this would be the first combination therapy for the disease. The application is backed by phase 3 SENTRY trial data showing significantly better spleen volume reduction with the combo versus ruxolitinib alone.
The FDA has accepted a supplemental new drug application (sNDA) for selinexor (Xpovio) combined with ruxolitinib (Jakafi) in patients with myelofibrosis, with a target action date of June 28, 2027. If approved, this would mark the first combination therapy ever cleared for the disease — a significant step forward given that JAK inhibitors have long been the only approved treatment class.
The application is supported by the phase 3 SENTRY trial, which enrolled JAK inhibitor–naïve patients with intermediate-to-high-risk, symptomatic myelofibrosis. Patients were randomized 2:1 to receive selinexor 60 mg weekly or placebo, both alongside ruxolitinib. While the coprimary endpoint of total symptom score improvement was not met, the spleen volume reduction endpoint was clearly achieved. An early overall survival signal also favored the combination, though follow-up remains too short for definitive conclusions.
By the Numbers:
Why it matters: Myelofibrosis patients have had limited options beyond JAK inhibitor monotherapy for years. A first-in-class approved combination could meaningfully change the treatment landscape for this difficult-to-treat blood cancer.